| Bioactivity | BG45 is a potent HDAC3 inhibitor with IC50 values of 0.289, 2, 2.2 and ﹥20 μM for HDAC3, HDAC1, HDAC2 and HDAC6, respectively. BG45 selectively targets multiple myeloma (MM) cells and induces caspase-dependent apoptosis[1][2]. | ||||||||||||
| Invitro | BG45 (1.875-30 µM; 48 and 72 h) targets multiple myeloma (MM) cells and inhibits cell growth in a dose-dependent manner[1].BG45 (15 µM; 0-48 h; MM.1S cells) induces apoptosis via caspase-3/PARP cleavage[1].BG45 (10 and 20 µM; 12 h; MM.1S cells) induces acetylation of histone H2A, H3, and H4 in a dose-dependent manner[1].BG45 (10 and 20 µM; 10 h; MM.1S cells) induces multiple myeloma (MM) cells toxicity is associated with hyperacetylation of histones and STAT3 and downregulation of p-STAT3[1]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| Name | BG45 | ||||||||||||
| CAS | 926259-99-6 | ||||||||||||
| Formula | C11H10N4O | ||||||||||||
| Molar Mass | 214.22 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|